Urology Practice Publishes Study Showing Oncotype DX® Increases Use of Active Surveillance in Prostate Cancer Patients by 56 Percent
Urology Practice published results from the second clinical utility study of the Oncotype DX® prostate cancer test, showing that incorporation of the test's Genomic Prostate Score (GPS) in treatment planning resulted in greater recommendations and acceptance of active surveillance as initial management of prostate cancer in low and low-intermediate risk patients.
"Despite increasing awareness of active surveillance as a viable alternative to immediate intervention in men with clinically low-risk prostate cancer, its adoption has been limited largely due to physician and patient concerns around the accuracy of disease risk assessment," said Marc Dall'Era, M.D., principal investigator of the study and vice chair of Urology at the University of California, Davis Comprehensive Cancer Center. "Our study showed that incorporation of the Oncotype DX results into clinical practice significantly increased the number of patients who chose active surveillance and avoided the adverse impact on quality of life that can result from invasive treatments, as well as their associated costs."
The multi-center study included 211 patients from 10 sites across the United States. The review of patient charts showed a relative increase of 56 percent in use of active surveillance in patients who received their Oncotype DX GPS compared to patients from the same practices with similar risk factors who were not tested.
Additionally, the results showed an increase in physician recommendation of active surveillance that was consistent with a previous prospective clinical study published earlier this year. Together, the two published clinical utility studies demonstrate that use of Oncotype DX changes both treatment recommendations and actual treatment received, resulting in greater recommendation and adoption of active surveillance.
"These data from actual patient charts add an important real-life perspective on the value of our test," said Phil Febbo, M.D., chief medical officer, Genomic Health. "Combined with 14 studies including more than 2,000 patients and a recent favorable draft local coverage determination on Medicare coverage, we believe this publication further supports our efforts to secure reimbursement for the Oncotype DX prostate cancer test."